|
private:synkinaseptyltd-2
|
1342067
|
Jun 3rd, 2019 12:00AM
|
SYNkinase Pty Ltd
|
53
|
2.00
|
Open
|
Biotechnology
|
Jun 3rd, 2019 05:12PM
|
Jun 3rd, 2019 05:12PM
|
SYNkinase’s mission is to provide life-science researchers with access to the world’s most up-to-date library of kinase inhibitors, and other small molecule inhibitors of important therapeutic proteins, for drug-discovery research use. With guidance from our founders, that include kinase biology scientists and expert medicinal and synthetic chemists, we have created a library of potent, pure and research-relevant inhibitors directed against specific protein serine/threonine kinases (PS/TKs), protein tyrosine kinases (PTK & RTK), as well as lipid kinases.
There are more than 150 Kinase targeted drugs in clinical trials or development at present. Twenty four small molecule inhibitors have been FDA-approved including mTOR, B-Raf, MEK, EGFR, JAK, VEGFR and PI3K inhibitors. SYNkinase has many of these compounds available for sale as well as a large range of inhibitors described in the literature such as GPCR and epigenetic inhibitors.
Importantly, as we are a primary source manufacturer we can maintain a fastidious focus on quality, as well as being first in the market with the most important and topical compounds. SYNkinase offers its inhibitor collections in several formats, including pre-formatted and custom arrays.
|
Open
|
Kinase Inhibitors, Small Molecule Inhibitors, Custom Synthesis, Medicinal Chemistry
|
Open
|
|
|
|
|
|
|
SYNkinase Pty Ltd
|
|
Health Care Equipment & Services
|
|
private:synkinaseptyltd-2
|
1342067
|
Nov 7th, 2017 12:00AM
|
SYNkinase Pty Ltd
|
37
|
2.00
|
Open
|
Biotechnology
|
Nov 7th, 2017 05:04PM
|
Nov 7th, 2017 05:04PM
|
SYNkinase’s mission is to provide life-science researchers with access to the world’s most up-to-date library of kinase inhibitors, and other small molecule inhibitors of important therapeutic proteins, for drug-discovery research use. With guidance from our founders, that include kinase biology scientists and expert medicinal and synthetic chemists, we have created a library of potent, pure and research-relevant inhibitors directed against specific protein serine/threonine kinases (PS/TKs), protein tyrosine kinases (PTK & RTK), as well as lipid kinases.
There are more than 150 Kinase targeted drugs in clinical trials or development at present. Twenty four small molecule inhibitors have been FDA-approved including mTOR, B-Raf, MEK, EGFR, JAK, VEGFR and PI3K inhibitors. SYNkinase has many of these compounds available for sale as well as a large range of inhibitors described in the literature such as GPCR and epigenetic inhibitors.
Importantly, as we are a primary source manufacturer we can maintain a fastidious focus on quality, as well as being first in the market with the most important and topical compounds. SYNkinase offers its inhibitor collections in several formats, including pre-formatted and custom arrays.
|
|
|
|
|
|
|
|
|
|
SYNkinase Pty Ltd
|
|
Health Care Equipment & Services
|
|
private:synkinaseptyltd-2
|
1342067
|
Nov 1st, 2017 12:00AM
|
SYNkinase Pty Ltd
|
37
|
2.00
|
Open
|
Biotechnology
|
Nov 1st, 2017 04:49AM
|
Nov 1st, 2017 04:49AM
|
SYNkinase’s mission is to provide life-science researchers with access to the world’s most up-to-date library of kinase inhibitors, and other small molecule inhibitors of important therapeutic proteins, for drug-discovery research use. With guidance from our founders, that include kinase biology scientists and expert medicinal and synthetic chemists, we have created a library of potent, pure and research-relevant inhibitors directed against specific protein serine/threonine kinases (PS/TKs), protein tyrosine kinases (PTK & RTK), as well as lipid kinases.
There are more than 150 Kinase targeted drugs in clinical trials or development at present. Twenty four small molecule inhibitors have been FDA-approved including mTOR, B-Raf, MEK, EGFR, JAK, VEGFR and PI3K inhibitors. SYNkinase has many of these compounds available for sale as well as a large range of inhibitors described in the literature such as GPCR and epigenetic inhibitors.
Importantly, as we are a primary source manufacturer we can maintain a fastidious focus on quality, as well as being first in the market with the most important and topical compounds. SYNkinase offers its inhibitor collections in several formats, including pre-formatted and custom arrays.
|
|
|
|
|
|
|
|
|
|
SYNkinase Pty Ltd
|
|
Health Care Equipment & Services
|